Moreover, AC133 monoclonal antibody (mAb) [49] and anti-CD44 antibody [44,50,51,52] conjugated with IRdye700 agents were used for NIR-PIT against different cancers by targeting cancer stem cell marker AC133 and CD44, respectively. The gene discussed is PROM1; the disease is cancer.